| |||||||||||||||||||||||||||||||||||||||||
| HIV-1 RNA < 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available). | |||||||||||||||||||||||||||||||||||||||||
Research Article
Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy
Table 1
Demographics and baseline characteristics of patients enrolled into the immunology substudy of GRACE.